Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

88 results about "Emoia loyaltiensis" patented technology

Nucleic acids encoding a recombinant 250 kDa antigen from sporozoites/merozoites of Eimeria maxima and their uses

The present invention provides an isolated nucleic acid comprising a nucleotide sequence encoding a 250 kDa polypeptide from Sporozoites/Merozoites of Eimeria maxima, or encoding a homolog of the polypeptide, or a complement of the nucleic acid and a method of producing a recombinant 250 kDa polypeptide of the same. The present invention also provides an isolated nucleic acid comprising a nucleotide sequence encoding an immunodominant portion of a 250 kDa polypeptide from Sporozoites/Merozoites of Eimeria maxima having the amino acid sequence described herein, or encoding a homolog of the polypeptide, or a complement of the nucleic acid. The subject invention also provides a vaccine against Eimeria tenella, Eimeria maxima, Eimeria acervulina, Eimeria necatrix, Eimeriapraecax, Eimeria mitis or Eimeria brunetti, or a microorganism expressing an immunologically cross-reactive antigen, comprising the isolated nucleic acid comprising a nucleotide sequence encoding a 250 kDa polypeptide from Sporozoites/Merozoites of Eimeria maxima or the immunodominant portion of a 250 kDa polypeptide from Sporozoites/Merozoites of Eimeria maxima, or encoding a homolog of the polypeptide, or a complement of the nucleic acid which may also contain a 56 kDa, 82 kDa or 230 kDa protein isolated from the gametocytes of Eimeria maxima and a method of immunizing a subject against infection by Eimeria tenella, Eimeria maxima, Eimeria acervulina, Eimeria necatrix, Eimeria praecox, Eimeria mitis or Eimeria brunetti, or a microorganism expressing an immunologically cross-reactive antigen, comprising the step of administering to the subject any of the aforementioned vaccines.
Owner:UNIV OF TECH SYDNEY

Application of secoisolariciresinol diglucoside in preparation of drug with resistance to eimeria tenella

InactiveCN106176779AGood against Eimeria tenellaThe anti-coccidian effect is obviousOrganic active ingredientsAccessory food factorsAnticoccidial AgentsEmoia loyaltiensis
The invention discloses an application of secoisolariciresinol diglucoside in preparation of a drug with resistance to eimeria tenella. Powder is prepared from the secoisolariciresinol diglucoside and acceptable auxiliary materials, is added to feed and is mixed uniformly, and chickens are fed according to the daily amount of feed; or water-soluble secoisolariciresinol diglucoside powder is prepared from the secoisolariciresinol diglucoside and dissolved in water, and the chickens are fed according to the daily drinking amount. Animal infection experiments prove that the ACI (anti-coccidial index) of the secoisolariciresinol diglucoside can be up to 165 or higher, and the secoisolariciresinol diglucoside has a better eimeria tenella resistant effect. Compared with a conventional anti-coccidial drug, namely, sulfachloropyrazin, the secoisolariciresinol diglucoside has a remarkable eimeria tenella resistant effect. According to the application of the secoisolariciresinol diglucoside, the problem of severe drug tolerance produced through adoption of the anti-coccidial drug in the current breeding industry can be effectively solved, the research and development speed of a new drug can be increased on the basis, and great benefits are provided for green and healthy development of the breeding industry.
Owner:广州市汇鑫动物药业有限公司

Preparation technology of chicken Eimeria tenella egg yolk antibody targeted sustained release preparation

ActiveCN103349782AImproved pharmacokinetic profileProlongs the duration of the effective concentrationAntibody ingredientsPharmaceutical non-active ingredientsCoccidiosisMass ratio
The invention relates to a chicken coccidiosis prevention and treatment preparation, in particular to a preparation technology of a chicken Eimeria tenella egg yolk antibody targeted sustained release preparation so as to solve the prevention and treatment problems of chicken coccidiosis. The preparation technology of the chicken Eimeria tenella egg yolk antibody targeted sustained release preparation includes the steps of: preparation, separation and purification of a highly immunized egg yolk antibody (IgY), and preparation of a microcapsule. Preparation of the microcapsule has the reaction conditions that: the chitosan concentration is 0.05-0.8% (w/v), the concentration of CaCl2 is 0.5-1.5% (w/v), the concentration of sodium alginate is 1.0-3.0% (w/v), and the IgY and the sodium alginate are in a mass ratio of 1-4:8. The IgY microcapsule prepared by the technical scheme involved in the invention is a preventive medicine, and is also a therapeutic drug. The microcapsule prepared by the invention provides a very good example for antibiotic substitution therapy. And the determined technology can also be used to prepare IgY or IgG microcapsules of other pathogenic microorganisms, thus having promotional value, and being beneficial to sound development of the green and organic chicken raising industry.
Owner:SHANXI AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products